Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients

Abstract

Tigecycline appears to be an effective therapy for severe infections due to CPKP in critically ill patients. Mortality is related to the severity of the underlying disease. We observed no benefit from a higher maintenance dose of tigecycline, although the number of patients included in the study was too small to draw any general conclusions in this regard.